美股异动｜辉瑞盘前涨1.6% 73亿美元收购Metsera，加码减肥药赛道

Group 1 - Pfizer (PFE.US) is reportedly close to acquiring weight loss drug company Metsera for $7.3 billion, with an initial cash payment of $47.50 per share and potential milestone payments of $22.50 per share, bringing the total valuation to $7.3 billion [1] - The acquisition offer represents a premium of approximately 110% over Metsera's closing price of $33.32 last Friday [1] Group 2 - As of September 19, Pfizer's stock closed at $24.030, with a pre-market price of $24.420, reflecting a 1.62% increase [1] - Pfizer's total market capitalization is approximately $136.62 billion, with a price-to-earnings ratio of 12.71 and a dividend yield of 7.07% [1]